Sanofi, buoyed by Dupixent and rare disease drugs, expects a brighter 2019

7th February 2019 Uncategorised 0

Sanofi’s growth momentum has returned after years of decline. With a major contribution from Dupixent—plus a renewed focus on oncology—Sanofi is looking at a brighter 2019.

More: Sanofi, buoyed by Dupixent and rare disease drugs, expects a brighter 2019
Source: fierce